Effectiveness of Metformin and its Combination with Probiotic in Polycystic Ovarian Disease with Hyperprolactinemia: A Randomized Clinical Trial

Abstract

Background: Polycystic ovarian syndrome (PCOS) is an endocrine disorder that predominantly affects women of the reproductive age. Anovulation and abnormal uterine bleeding are caused by hyperprolactinemia, which affects the hypothalamic-pituitary-ovarian axis. Aim: In this study, the efficacy of combined Probiotic and Metformin therapy on hyperprolactinemia levels in PCOS patients was compared to Metformin therapy alone. Methodology: 102 participants having hyperprolactinemia were enrolled via convenient sampling technique between January 2019 to August 2019. Out of them women having Polycystic Ovarian Syndrome (PCOS) and high serum prolactin levels were randomly assigned to one of two groups: group one received oral Metformin tablet 500 mg T.D. for three months, and group two received oral Metformin tablet 500 mg T.D  and Probiotic capsule 180 mg O.D for three months. Serum prolactin levels in both groups were compared before and after treatment. Results: 54 (53%) of the 102 hyperprolactinemia women had PCOS. The Combination group showed improvement in reduction in hyperprolactinemia levels after 12 weeks of intervention. Conclusion: The addition of Probiotic to Metformin improved prolactin levels in women with polycystic ovarian syndrome with hyperprolactinemia more than Metformin alone.